During biliary disease, cholangiocytes become activated by various pathological stimuli, including transforming growth factor β (TGF-β). The result is an epigenetically regulated transcriptional program leading to a pro-fibrogenic microenvironment, activation of hepatic stellate cells (HSCs), and progression of biliary fibrosis. This study evaluated how TGF-β signaling intersects with epigenetic machinery in cholangiocytes to support fibrogenic gene transcription. We performed RNA sequencing in cholangiocytes with or without TGF-β. Ingenuity pathway analysis identified "HSC Activation" as the highly up-regulated pathway, including overexpression of fibronectin 1 (FN), connective tissue growth factor, and other genes. Bioinformatics identified enhancer of zeste homologue 2 (EZH2) as an epigenetic regulator of the cholangiocyte TGF-β response. EZH2 overexpression suppressed TGF-β-induced FN protein in vitro, suggesting FN as a direct target of EZH2-based repression. Chromatin immunoprecipitation assays identified an FN promoter element in which EZH2-mediated tri-methylation of lysine 27 on histone 3 is diminished by TGF-β. TGF-β also caused a 50% reduction in EZH2 protein levels. Proteasome inhibition rescued EZH2 protein and led to reduced FN production. Immunoprecipitation followed by mass spectrometry identified ubiquitin protein ligase E3 component N-recognin 4 in complex with EZH2, which was validated by western blotting in vitro. Ubiquitin mutation studies suggested K63-based ubiquitin linkage and chain elongation on EZH2 in response to TGF-β. A deletion mutant of EZH2, lacking its N-terminal domain, abrogates both TGF-β-stimulated EZH2 degradation and FN release. In vivo, cholangiocyte-selective knockout of EZH2 exacerbates bile duct ligation-induced fibrosis whereas MDR2-/- mice are protected from fibrosis by the proteasome inhibitor bortezomib. Conclusion: TGF-β regulates proteasomal degradation of EZH2 through N-terminal, K63-linked ubiquitination in cholangiocytes and activates transcription of a fibrogenic gene program that supports biliary fibrosis.
During biliary disease, cholangiocytes become activated by various pathological stimuli, including transforming growth factor β (TGF-β). The result is an epigenetically regulated transcriptional program leading to a pro-fibrogenic microenvironment, activation of hepatic stellate cells (HSCs), and progression of biliary fibrosis. This study evaluated how TGF-β signaling intersects with epigenetic machinery in cholangiocytes to support fibrogenic gene transcription. We performed RNA sequencing in cholangiocytes with or without TGF-β. Ingenuity pathway analysis identified "HSC Activation" as the highly up-regulated pathway, including overexpression of fibronectin 1 (FN), connective tissue growth factor, and other genes. Bioinformatics identified enhancer of zeste homologue 2 (EZH2) as an epigenetic regulator of the cholangiocyte TGF-β response. EZH2 overexpression suppressed TGF-β-induced FN protein in vitro, suggesting FN as a direct target of EZH2-based repression. Chromatin immunoprecipitation assays identified an FN promoter element in which EZH2-mediated tri-methylation of lysine 27 on histone 3 is diminished by TGF-β. TGF-β also caused a 50% reduction in EZH2 protein levels. Proteasome inhibition rescued EZH2 protein and led to reduced FN production. Immunoprecipitation followed by mass spectrometry identified ubiquitin protein ligase E3 component N-recognin 4 in complex with EZH2, which was validated by western blotting in vitro. Ubiquitin mutation studies suggested K63-based ubiquitin linkage and chain elongation on EZH2 in response to TGF-β. A deletion mutant of EZH2, lacking its N-terminal domain, abrogates both TGF-β-stimulated EZH2 degradation and FN release. In vivo, cholangiocyte-selective knockout of EZH2 exacerbates bile duct ligation-induced fibrosis whereas MDR2-/- mice are protected from fibrosis by the proteasome inhibitor bortezomib. Conclusion: TGF-β regulates proteasomal degradation of EZH2 through N-terminal, K63-linked ubiquitination in cholangiocytes and activates transcription of a fibrogenic gene program that supports biliary fibrosis.
Authors: W Lu; S Liu; B Li; Y Xie; M G Izban; B R Ballard; S A Sathyanarayana; S E Adunyah; R J Matusik; Z Chen Journal: Oncogene Date: 2016-11-21 Impact factor: 9.867
Authors: Thiago M De Assuncao; Yan Sun; Nidhi Jalan-Sakrikar; Mary C Drinane; Bing Q Huang; Ying Li; Jaime I Davila; Ruisi Wang; Steven P O'Hara; Gwen A Lomberk; Raul A Urrutia; Yasuhiro Ikeda; Robert C Huebert Journal: Lab Invest Date: 2015-04-13 Impact factor: 5.662
Authors: Edward Y Chen; Christopher M Tan; Yan Kou; Qiaonan Duan; Zichen Wang; Gabriela Vaz Meirelles; Neil R Clark; Avi Ma'ayan Journal: BMC Bioinformatics Date: 2013-04-15 Impact factor: 3.169
Authors: Amaia Navarro-Corcuera; Tejasav S Sehrawat; Nidhi Jalan-Sakrikar; Hunter R Gibbons; Nicholas E Pirius; Shalil Khanal; Feda H Hamdan; Sayed Obaidullah Aseem; Sheng Cao; Jesus M Banales; Ningling Kang; William A Faubion; Nicholas F LaRusso; Vijay H Shah; Robert C Huebert Journal: J Hepatol Date: 2021-12-23 Impact factor: 25.083
Authors: Nidhi Jalan-Sakrikar; Thiago M De Assuncao; Amaia Navarro-Corcuera; Feda H Hamdan; Lorena Loarca; Lindsey A Kirkeby; Zachary T Resch; Steven P O'Hara; Brian D Juran; Konstantinos N Lazaridis; Charles B Rosen; Julie K Heimbach; Timucin Taner; Vijay H Shah; Nicholas F LaRusso; Robert C Huebert Journal: Hepatol Commun Date: 2021-08-25
Authors: Sayed Obaidullah Aseem; Nidhi Jalan-Sakrikar; Cheng Chi; Amaia Navarro-Corcuera; Thiago M De Assuncao; Feda H Hamdan; Shiraj Chowdhury; Jesus M Banales; Steven A Johnsen; Vijay H Shah; Robert C Huebert Journal: Gastroenterology Date: 2020-10-12 Impact factor: 22.682